ABIVAX Société Anonyme

(PINK:AAVXF)

Latest On ABIVAX Société Anonyme (AAVXF):

Date/Time Type Description Signal Details
2022-03-18 09:27 ESTNewsABIVAX Société Anonyme reports FY resultsN/A
2022-01-19 23:16 ESTNewsAbivax ABX196 shows benefit in liver cancer patients in phase 1/2 trialN/A
2021-12-16 00:57 ESTNewsAbivax: Potentially The Next Arena Pharmaceuticals, Most Ideal Big Pharma M&A Target In 2022N/A
2021-07-23 13:29 ESTNewsAbivax prices oversubscribed capital increase of €60M and €85M in convertible bondsN/A
2021-07-22 16:47 ESTNewsAbivax reports strong phase 2 data on ulcerative colitis candidate; shares up 12%N/A
2021-04-14 20:05 ESTNewsAbivax completes induction treatment in phase 2 ulcerative colitis trial of ABX464N/A
2021-03-07 02:00 ESTNewsABIVAX halts COVID-19 trial after finding lack of efficacyN/A
2020-12-04 06:19 ESTFinancialsCompany financials have been released.Neutral
2020-11-27 00:35 ESTFinancialsCompany financials have been released.Neutral
2020-10-08 20:55 ESTFinancialsCompany financials have been released.Neutral
2020-10-04 15:18 ESTFinancialsCompany financials have been released.Neutral
2020-10-03 11:48 ESTFinancialsCompany financials have been released.Neutral
2020-09-27 06:55 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 16:31 ESTFinancialsCompany financials have been released.Neutral
2020-09-25 09:32 ESTNewsABIVAX Société Anonyme reports 1H resultsN/A
2020-09-17 09:11 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 12:36 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 16:18 ESTFinancialsCompany financials have been released.Neutral
2020-08-04 19:34 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 11:58 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 04:23 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 20:33 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 08:24 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 00:41 ESTFinancialsCompany financials have been released.Neutral
2020-07-28 16:18 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 16:15 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 21:05 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 12:27 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 07:26 ESTFinancialsCompany financials have been released.Neutral
2020-07-02 23:29 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 20:05 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 03:57 ESTFinancialsCompany financials have been released.Neutral
2020-06-25 07:19 ESTFinancialsCompany financials have been released.Neutral
2020-06-22 17:43 ESTNewsStudy of Abivax COVID-19 drug expanded to BrazilN/A
2020-06-19 15:56 ESTFinancialsCompany financials have been released.Neutral
2020-06-15 16:56 ESTNewsAbivax receives non-dilutive financingN/A
2020-06-14 08:09 ESTFinancialsCompany financials have been released.Neutral
2020-06-12 09:42 ESTFinancialsCompany financials have been released.Neutral
2020-06-07 19:42 ESTFinancialsCompany financials have been released.Neutral
2020-06-05 15:27 ESTFinancialsCompany financials have been released.Neutral
2020-06-03 19:19 ESTFinancialsCompany financials have been released.Neutral
2020-05-27 08:45 ESTFinancialsCompany financials have been released.Neutral
2020-05-21 04:31 ESTFinancialsCompany financials have been released.Neutral
2020-05-14 03:45 ESTFinancialsCompany financials have been released.Neutral
2020-05-07 11:28 ESTFinancialsCompany financials have been released.Neutral
2020-05-07 03:47 ESTFinancialsCompany financials have been released.Neutral
2020-05-06 09:09 ESTFinancialsCompany financials have been released.Neutral
2020-05-02 23:37 ESTFinancialsCompany financials have been released.Neutral
2020-05-01 19:55 ESTFinancialsCompany financials have been released.Neutral
2020-04-30 11:08 ESTNewsABIVAX Société Anonyme reports FY resultsN/A

About ABIVAX Société Anonyme (AAVXF):

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the development of ABX 544, a drug candidate for the treatment of Ebola based on polyclonal antibodies; and research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was founded in 2013 and is headquartered in Paris, France.

See Advanced Chart

General

  • Name ABIVAX Société Anonyme
  • Symbol AAVXF
  • Type Common Stock
  • Exchange PINK
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 27
  • Fiscal Year EndDecember
  • Web URLhttp://www.abivax.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 16857.84
  • Price/Book (Most Recent Quarter) 47.3
  • Enterprise Value Revenue 24466.82
View More

Financials

  • Most Recent Quarter 2020-06-30
  • Return on Assets -39%
  • Return on Equity -209%
  • Earnings Per Share -$1.51
  • Revenue Per Share $0
  • Gross Profit -28186000
  • Quarterly Earnings Growth 15%
View More

Highlights

  • Market Capitalization 342.34 million
  • Book Value Per Share $4.80
View More

Share Statistics

  • Shares Outstanding 14.38 million
  • Shares Float 5.33 million
  • % Held by Insiders 687%
  • % Held by Institutions 53.57%
View More

Technicals

  • Beta 1.15
  • 52 Week High $43.97
  • 52 Week Low $13.15
  • 50 Day Moving Average 34.51
  • 200 Day Moving Average 36.15
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

ABIVAX Société Anonyme (AAVXF) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

ABIVAX Société Anonyme (AAVXF) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-03-312020-06-30$N/A-$0.71$0.00
2019-12-312020-03-31$-20000-$0.70$0.00
2019-09-302019-12-31$-20000-$0.76$0.00
2019-06-302019-09-30$20000-$0.74$0.00
2019-03-312019-06-30$20000-$0.79$0.00
2018-12-312019-03-31$161500-$0.78$0.00
2018-09-302018-12-31$161500-$0.48$0.00
2018-06-302018-09-30$246000-$0.49$0.00
2018-03-312018-06-30$246000-$0.42$0.00
2017-12-312018-03-31$176500-$0.45$0.00
2017-09-302017-12-31$176500-$0.34$0.00
2017-06-302017-09-30$2000-$0.34$0.00
2017-03-312017-06-30$2000-$0.33$0.00
2016-12-312017-03-31$7000-$0.30$0.00
2016-09-302016-12-31$7000-$0.33$0.00
2016-06-302016-09-30-$0.35$0.00
2016-03-312016-06-30-$0.48$0.00
2015-12-312016-03-31-$0.49$0.00
2015-09-302015-12-31-$0.49$0.00
2015-06-302015-09-30-$0.51-$0.32-58.69%
2015-03-312015-06-30-$0.41$0.00
2014-12-312015-03-31-$0.40$0.00
2014-09-302014-12-31-$0.39$0.00
2014-06-302014-09-30-$0.40$0.00

ABIVAX Société Anonyme (AAVXF) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

ABIVAX Société Anonyme (AAVXF) Chart:

ABIVAX Société Anonyme (AAVXF) News:

Below you will find a list of latest news for ABIVAX Société Anonyme (AAVXF) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

ABIVAX Société Anonyme (AAVXF) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

ABIVAX Société Anonyme (AAVXF) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link